A multicenter, prospective, phase 2 trial on proton re‐irradiation for patients with previously treated head and neck cancer
Cancer · 01.11.2026 · 132 (21)
DOI: 10.1002/cncr.70643 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 30.10.2026. Verfasst von Edward Christopher Dee und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Proton Therapy, Re-Irradiation, Neoplasm Recurrence, Local. Die Arbeit nennt 41 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Re‐irradiation (re‐RT) for recurrent head and neck cancer (HNC) can be potentially curative but is constrained by significant toxicity. Proton therapy may improve the therapeutic ratio. This multicenter phase 2 trial evaluated the safety and efficacy of proton re‐RT in patients with HNC.
Methods
Patients received prior HNC radiotherapy at a dose of ≥40 gray (Gy). Salvage surgery and/or systemic therapy before re‐RT were permitted. Considering clinical status, two pragmatic treatment approaches were used: fractionated re‐RT (F‐Re‐RT; 60–70 Gy) or QUAD shot re‐RT (QS‐Re‐RT; 14.8 Gy per cycle, up to four cycles; maximum total, 59.2 Gy). Primary end points were locoregional recurrence–free rates at 12 months for F‐Re‐RT and at 6 months for QS‐Re‐RT, and a fixed‐time, binary proportion analyzed using 90% Clopper–Pearson confidence intervals (CIs) and prespecified success thresholds (lower bound, >55% and >10%, respectively). Secondary end points included overall survival (OS), progression‐free survival, the cumulative incidence of distant metastasis and locoregional recurrence, clinician‐reported toxicity, and patient‐reported outcomes.
Results
From July 2017 to November 2022, 85 patients received either F‐Re‐RT ( n = 57) or QS‐Re‐RT ( n = 28), with a median follow‐up of 38 months. The locoregional recurrence–free rates were 71% (90% CI, 59%–81%) at 12 months for F‐Re‐RT and 76% (90% CI, 58%–89%) at 6 months for QS‐Re‐RT, surpassing prespecified success thresholds. The highest late toxicity attributable to re‐RT was grade 3 in 20% of patients, grade 4 in 11%, and grade 5 in 4%. The 5‐year OS rate was 29%, and the 5‐year progression‐free survival rate was 23%. Patient‐reported outcomes were stable at 1 year after F‐Re‐RT and after QS‐Re‐RT.
Conclusions
Proton re‐RT demonstrated encouraging locoregional control and survival in heavily pretreated patients, although late toxicities remain important concerns (ClinicalTrials.gov identifier: NCT03217188).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Radiation Oncology, Miami Cancer Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- New York Proton Center, New York, New York, USA.
- Department of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.
- Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Edward Christopher Dee, Yao Yu, Jung Julie Kang, Lara A Dunn, Alan L Ho, Marc A Cohen, Ian Ganly, Jennifer R Cracchiolo, Eric J Sherman
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Dee, E. C., Barker, C. A., Kalman, N. S., Wu, Y., White, C., Zhang, Z., Lin, H., Gelblum, D. Y., Yu, Y., Kang, J. J., Tsai, C. J., Zakeri, K., Chen, L., McBride, S. M., Shamseddine, A., Michel, L. S., Dunn, L. A., Ho, A. L., Cohen, M. A., …, & Lee, N. Y. (2026). A multicenter, prospective, phase 2 trial on proton re‐irradiation for patients with previously treated head and neck cancer. Cancer, 132(21). https://doi.org/10.1002/cncr.70643
Vancouver
Dee EC, Barker CA, Kalman NS, Wu Y, White C, Zhang Z, et al. A multicenter, prospective, phase 2 trial on proton re‐irradiation for patients with previously treated head and neck cancer. Cancer. 2026;132(21). doi:10.1002/cncr.70643
BibTeX
@article{Dee2026,
author = {Dee, Edward Christopher and Barker, Christopher A and Kalman, Noah S and Wu, Yingzhi and White, Charlie and Zhang, Zhigang and Lin, Haibo and Gelblum, Daphna Y and Yu, Yao and Kang, Jung Julie and Tsai, C Jillian and Zakeri, Kaveh and Chen, Linda and McBride, Sean M and Shamseddine, Achraf and Michel, Loren S and Dunn, Lara A and Ho, Alan L and Cohen, Marc A and Ganly, Ian and Cracchiolo, Jennifer R and Wong, Richard J and Romesser, Paul B and Riaz, Nadeem and Sherman, Eric J and Lee, Nancy Y},
title = {A multicenter, prospective, phase 2 trial on proton re‐irradiation for patients with previously treated head and neck cancer},
journal = {Cancer},
year = {2026},
volume = {132},
number = {21},
doi = {10.1002/cncr.70643}
}
EUVIMED